Maegim한국어

유유제약

000220KOSPISector: Pharma & Biotech
₩3,640▲ 1.25%Market cap ₩57.3BAs of Jul 21, 2026 close · updated once daily
A
Grade A71.1 ptsTop 10% of 2,523 stocks
Financial strength
62.9
Growth momentum
54.9
Price attractiveness
91.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

62.9
How much debt does it carry relative to equity?
Debt-to-equity ratio
47.4%
✓ Above median · Top 46.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
164.4%
✗ Below median · Top 55.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
7.8%
✓ Above median · Top 22.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
6.3%
✓ Above median · Top 24.2% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

54.9
How much did revenue grow in a year?
Revenue growth (YoY)
5.8%
✗ Below median · Top 53.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
0.5%
✗ Below median · Top 66.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-5.8%
✗ Below median · Top 58.7% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
1961.0%
✓ Above median · Top 1.3% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

91.9
Is the price expensive relative to earnings?
P/E (price-to-earnings)
7.0x
✓ Above median · Top 7.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.44x
✓ Above median · Top 8.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15